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ABBREVIATIONS 
TGF-/3 transforming growth factor-beta 
DMEM Dulbecco-vogt's modified eagle's medium 
SDS sodium dodecyl sulfate 
EGF epidermal growth factor 
FGF fibroblast growth factor 
ECM extracellular matrix 
CM conditioned medium 
HSPG heparan sulfate proteoglycan 
BSA bovine serum albumin 
EtOH ethanol 
^H-TdR tritiated thymidine 
PAGE polyacrylamide gel electrophoresis 
PAI-1 type 1 plasminogen activator inhibitor 
Unit (TGF-)S) one unit of TGF-jS activity is defined as 
the amount of TGF-p needed to cause a 
50% reduction of DNA synthesis in 
CCL 64 cells 
Unit (plasmin) one unit of plasmin is defined as 
the amount of enzyme that will hydrolyze 
1 /imol of tosyl-Gly-Pro-Lys-PNA per 
minute at 25°C, pH 7.8 
HPLC high pressure liquid chromatography 
RPLC reverse phase HPLC 
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GENERAL INTRODUCTION 
Explanation of Thesis Format 
The following thesis was prepared according to the 
alternate format style. An abstract and general introduction 
precedes two independent journal style papers that will be 
submitted for publication. A general summary and biblio­
graphy concludes the thesis. The work described in the 
papers was performed entirely by this author under the 
supervision and in the lab of Marit Nilsen-Hamilton. The 
first paper describes the purification and characterization 
of an extracellular matrix associated growth inhibitor named 
matrixin-A that is released by proteolytic degradation of the 
ECM. The second paper details a simple high yield 
purification of transforming growth factor-)8 from bovine 
platelets and a novel, specific bioassay for TGF-p activity. 
The primary goal of this project is to understand the 
interactive role of growth factors and extracellular matrix 
(ECM) in the regulation of cell proliferation. The ECM is 
typically viewed as a complex mixture of structural proteins 
secreted by cells to form a network in which to live. The 
ECM has the ability to interact with cell membranes providing 
a surface for attachment of adhesive cells. But the ECM has 
many facets. It not only provides structural support but can 
act as a reservoir for physiologically relevant molecules 
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that can mediate cellular processes when released or activat­
ed. It can concentrate and orient these molecules in order 
to function properly. These molecules include proteases, 
their inhibitors and growth factors as well as many of the 
structural components themselves. 
The three major components of the ECM consist of colla­
gen, proteoglycans and glycoproteins. Collagen is secreted 
by fibroblasts and consists of a triple helix of two types of 
chains, a-l and a-2. The protein is highly conserved, insol­
uble and very stable (reviews: Ruoslahti et ^ ., 1985; Ruos-
lahti, 1989; Hay, 1981). There are five well characterized 
collagen types that are constituted of combinations of the 
two chains. Various tissues are found to have a distinct 
complement of collagen. Relevant to this research are type-
IV collagen that makes up the basement laminae of epithelial 
and endothelial cells and type-I collagen that is widespread 
and is a major component of skin, tendon, bone and fascia. 
Collagen is very stable and turns over very slowly 
except in regions where tissue remodeling, growth or cell 
invasion is occurring. Type-IV collagen is degraded by the 
action of specific collagenases and is resistant to other 
proteinases (Sale et a%., 1982). Specific proteolysis is a 
common theme amongst ECM components as it provides highly 
regulated degradation ô£ the ECM. Procollagenases reside in 
the ECM in a latent form and can be activated by proteolysis, 
treatment with sulfhydryl agents and by auto-activation 
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(Harris et al., 1984). The serine protease plasmin is found 
to activate Type-IV collagenase and may be a key step in 
tissue remodeling (Tryggvason, et al., 1987; Laiho and Keski-
Oja, 1989). 
Collagen may not be just a structural protein. Studies 
have indicated that collagen may inhibit cell proliferation 
(Nugent and Newman, 1989; Rhudy and McPherson, 1988; Kindy, 
et al.. 1988). Collagen may work directly through cell 
surface binding proteins to inhibit proliferation (Dedhar et 
al., 1987) or to alter cell shape which could possibly affect 
proliferation (Gospodarowicz et , 1978). Type I collagen 
gels induce the transcription factors HNF3a and eH-TF in the 
hepatocyte derived cell line H2.35. These transcription 
factors can in turn activate liver specific genes such as 
albumin (DiPersio et al., 1991). The ECM may directly 
activate a signal transduction pathway that can modulate gene 
transcription. 
Another major component of the ECM is the proteogly­
cans. These are a complex series of proteins to which long 
glycoaminoglycan (GAG) chains are attached. The size and 
shape of proteoglycans varies greatly depending on the GAG 
complement. The polysaccharide unit of GAG consist of 
repeating disaccharide units that contain either 
D-glucosamine and or D-galactosamine in conjunction with 
uronic acid, L-glucuronic acid, or L-iduronic acid 
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(for review see; Murray et al., 1988). Except for the 
proteoglycan, hyaluronic acid, the polysaccharides of the 
component GAGs contain many sulfate groups, which provides 
them with a highly polyanionic character. The polysaccharide 
groups in proteoglycans are covalently attached to a protein 
via a unique xylose to serine bond, a serine to galactosamine 
bond or an asparagine to glucosamine bond. These unique 
bonds make proteoglycans unique from glycoproteins. Many 
GAGs attach to a central core protein to compose the proteo­
glycan. Once formed in the ECM, proteoglycans can be degrad­
ed by a complex battery of enzymes consisting of endo and 
exo-glycosidases. Degradation and turnover of proteoglycan 
are important as there are many inherited disorders that 
involve the inability to degrade proteoglycan. 
Cells adhere to the ECM via attachment sites that are 
partially composed of proteoglycan. The GAG of the proteogly­
can give it the capacity for multiple non-covalent binding of 
proteins and cells. The proteoglycan also binds to soluble 
proteins to stabilize, concentrate and orient them. Heparan 
sulfate binds to growth factors such as FGF (Saksela et al., 
1988; Saksela and Rifkin, 1990), retinal survival factor and 
Schwan cell growth factor (Herman et al., 1987; Ratner et 
al. . 1988). Betaglycan binds TGF-/?- (Boyd and Massaguè, 1989) 
and FGF.(Massague et al., 1992). The binding of growth 
factors may explain in part the growth regulatory properties 
of the ECM. 
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The proteoglycans heparin and heparan sulfate can inhib­
it cell proliferation (Castellot et al., 1982; Ishihara et 
al.. 1987). Heparin's GAG component contains a repeating 
disaccharide unit of glucosamine and uronic acid attached to 
a protein core composed entirely of serine and glycine. The 
size varies form 1 to 1000 KDa and is found predominately in 
storage granules within mast cells. Heparin can inhibit 
coagulation by its binding antithrombin III and increasing 
its affinity for thrombin. Because heparin is stored intra-
cellularly it may not play a physiological role in ECM con­
trol of cell proliferation (Ruoslahti, 1989) . 
Of more physiologic relevance is heparan sulfate. 
Heparan sulfate is very similar to heparin. Heparan sulfate 
differs in its amino acid compliment and has more glucuronic 
acid as opposed to iduronic acid of heparin. Heparan sulfate 
is found both in the ECM and on the cell surface periphery 
whereas heparin is stored intracellularly in granules of mast 
cells. It can inhibit arterial smooth muscle cells, 
endothelial cells and hepatocytes (Ishihara et al., 1986). 
Although the mechanism of growth inhibition is unknown, 
evidence suggests that inhibition depends on internalization 
of heparan sulfate by the cell (Ruoslahti, 1989). The GAG of 
this proteoglycan once inside the cell seems to affect 
chromatin structure and can activate DNA polymerase in vitro 
(Murray et , 1988). The effects of heparan sulfate are 
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cell type dependent because it is found to stimulate the 
proliferation of some cells. This makes heparan sulfate 
functionally similar to TGF-p with its bifunctional nature. 
The bifunctional nature of heparan sulfate could be the 
consequence of how the protein is processed once internal­
ized. Differential processing or degradation could free 
moieties that could enter the nucleus to either inhibit or 
stimulate proliferation. 
The growth effects could also be attributed to the 
complement of growth factors bound to the proteoglycan. Both 
acidic and basic fibroblast growth factor (FGF) tightly bind 
to heparan sulfate. Complexes between FGF and HSPG (heparan 
sulfate proteoglycan) have been found in the ECM of bovine 
capillary endothelial cells (Saksela and Rifkin, 1990). The 
HSPG stabilizes or concentrates the FGF enhancing it activity 
and providing a reservoir of the growth factor. Saksela and 
Rifkin have shown that the release of active soluble FGF-
HSPG complexes can be mediated by plasmin. This would 
provide a controlled means of releasing growth factor 
wherever the plasminogen activation cascade is activated such 
as the site of a wound where controlled cell proliferation is 
needed. 
TGF-/3 may also bind to the ECM and or the cell surface 
via proteoglycans. One of the three cellular receptors for 
TGF-)9 is betaglycan (Andres et , 1989). TGF-/3 does not 
functionally act via betaglycan. Betaglycan contains a 
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distinct TGF-/3 binding domain on the core protein which is 
distinct from the region of GAG binding (Cheifetz et al., 
198 8). The GAG component consists of chondroitin sulfate and 
heparan sulfate. Betaglycan is probably a storage or trans­
port protein for TGF-/3 (for review see Massaguè, 1990) . 
Betaglycan is a 250 to 350 KDa integral membrane protein that 
contains a membrane anchor domain. A variant form has been 
found that is missing the anchor domain allowing the protein 
to freely circulate (Segarini and Seyedin, 1988) . This 
soluble form is found in serum, cell culture medium and 
extracellular matrix of CCL39 (Hamster fibroblast), RAT-1 
(lung fibroblast), 3T3-L1 (adipocytes and fibroblasts) cells 
(Andres et al., 1989). The GAG component of betaglycan may 
be the ECM binding moiety providing a means in which TGF-j3 
can be bound to the ECM for possible storage and stabiliza­
tion. It remains to be determined if TGF-j8 binds to the ECM 
through betaglycan and whether TGF-)3 is releasable or active 
in this state. 
The last major component of the ECM are various glyco­
proteins such as fibronectin, laminin and vitronectin (re­
view, Ruoslahti et al., 1985). These proteins have cell 
surface receptor and can also bind the ECM. They promote the 
attachment of cells to the ECM and allow cell spreading. 
Important to cell growth is cell spreading and cell attach­
ment. Fibronectin is a 250 KDa protein secreted by many cells 
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and is found in both plasma and tissues (Hayman and Ruos-
lahti, 1979) . The cell attachment activity of fibronectin 
depends on a tripeptide domain Arg-Gly-Asp (RGD, Pierschbach-
er et al., 1981). This sequence can promote attachment, 
inhibit binding of cells to fibronectin and is also found in 
type I collagen and vitronectin. This sequence is recognized 
by the cell surface receptor for the mentioned glycoproteins. 
The RGD site is recognized by a family of cell surface 
receptors called the integrins (for review see: Ruoslahti, 
1988). Four integrins have been well characterized. They 
include human osteosarcoma/fibroblast receptor, human hepato-
cyte receptor, human platelet agggregation receptor and the 
chicken integrin complex. Each type is cell specific and 
bind differentially to fibronectin and other ECM components. 
The human hepatocyte receptor binds mainly to fibronectin but 
the platelet aggregation receptor binds fibronectin, fibrino­
gen, vitronectin and von Willebrand factor. Each receptor 
consists of a dimer of two subunits a and /3. The subunits 
have large extracellular domains in which to bind ECM compo­
nents, a cell membrane spanning domain and a small cytoplas­
mic domain. The cytoplasmin domain of the j0 subunit is 
highly conserved amongst integrins characterized to date and 
contains a potential tyrosine phosphorylation site homologous 
to that found for EGF and insulin receptors (Tamkun et al., 
1986). This site may link the integrins and the ECM to 
signal transduction pathways that involve tyrosine kinase. 
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Virally transformed chicken fibroblasts have been found to 
have their chicken integrin complex phosphorlyated 
(Hirst et al., 1986). The phosphorylation of the integrin 
may play a role in affinity and specificity of the integrin 
interaction with the ECM. Also the cytoplasmic domain has 
affinity for the cytoskelatal protein talin indicating a 
possible link between the ECM and the cytoskeleton (Horwitz 
et al., 1986). 
Plasminogen is the inactive zymogen of the serine pro­
tease plasmin. Plasminogen is a glycoprotein of about 92 KDa 
made in the kidney and found in most tissues and plasma 
usually associated with fibrinogen at circulating levels of 
about 12 mg/deciliter, for reviews see Laiho and Keski-Oja, 
1989; Collen and Lijnen, 1985; Saksela, 1985. The zymogen is 
activated in a process termed the plasminogen activation 
cascade by the action of tissue type plasminogen activator 
(t-PA) and urokinase type plasminogen activator (u-PA). The 
process of activation requires the cleavage of a Argggg-
Val56i bond in the proenzyme resulting in a two-chain active 
plasmin molecule. 
The specificity of plasmin is similar to trypsin. It 
acts primarily on fibrin to degrade clots in the process of 
fibrinolysis. Plasminogen is usually associated with 
fibrinogen and contains fibrinogen binding domains consisting 
of lysine binding sites on the kringle loop structures that 
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are ultimately located in the plasmin A chain. The plasmin 
B-chain contains the active site and is derived from the 
C-terminal portion of plasminogen. Plasmin recognizes and 
cleaves on the C-terminal side of either X-Arg-Y or -Lys-Y 
bonds. 
Circulating free plasmin has an estimated half life 
of 100 msec whereas fibrin bound plasmin is much more stable 
at 10 to 100 seconds (Collen, 1980). Inactivation of plasmin 
is primarily the result of circulating plasmin inhibitors. 
The two main inhibitors are a-2-antiplasmin and a-2-macro-
globulin. Other serine protease inhibitors can inhibit 
plasmin including a-l-antitrypsin, antithrombin III, inter-
alpha-trypsin inhibitor and C-1 esterase inhibitor. Based 
upon kinetic analysis it has been proposed that a-2-antiplas-
min at a circulating level of 1.0 fxK is the primary, fast 
acting inhibitor of plasmin (1.5 juM) . Once o:-2-antiplasmin 
is exhausted the slow acting a-2-macroglobulin acts to 
inhibit the residual plasmin (Collen and Lijnen, 1985). The 
fast and slow acting nomenclature is based upon clot lysis 
assays (for review see: Collen and Lijnen, 1978; Wiman, 
1981). Inhibitor binding involves the kringle domains of 
plasmin and blockage of the kringle domains can prevent 
binding to fibrin. 
The matrix localization of plasminogen and plasmin 
activity may play a major role in metastasis of tumor cells 
and cell invasion during tissue formation. For cells to 
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invade an area they must be able to penetrate basement 
membranes and cell junctions. The penetration depends on the 
dissolution of the barrier by the combined actions of col-
lagenases, elastases, glycanases and plasmin (Moscatelli and 
Rifkin, 1988; Liotta et , 1981). The importance of pro­
tease localization during metastasis was demonstrated when 
it was found that antibody inhibitors of plasmin and collage-
nase could prevent the protease mediated cell invasion of 
tumor cells into amnion membranes only when the cells were 
pretreated with the inhibitors. They were not effective in 
inhibiting cell invasion when cells were attached to the 
membranes prior to antibody treatment. Presumably once 
attached the cells masked the sites of protease activity from 
the antibodies allowing degradation and invasion of the 
amnion (Mignatti et , 1986) . 
Transforming growth factor-)9 is a peptide growth factor 
that may be associated with the ECM through its receptor 
betaglycan (Andres et , 1989). TGF-)3 is a 25 KDa dimer 
secreted by a variety of cells both normal and transformed 
(Roberts and Sporn, 1988; Massaguè, 1990; Nilsen-Hamilton, 
1990) and can be found in high concentrations in bone and 
platelets predominately in a latent form. TGF-/3 is a multi­
functional regulator of growth and differentiation. It can 
both inhibit DNA synthesis of cells and stimulate the prolif­
eration of some fibroblast cell lines. TGF-jS can cause the 
12 
differentiation of many cells including pre-adipocytes into 
adipocytes, bronchial epithelial cells into squamous cells 
and mesenchymal cells into bone. 
Transforming growth factor-jS is produced and secreted by 
many cell types as latent dimer consisting of two disulfide 
linked monomers of 361 amino acid residues each (Derynck et 
al.. 1985; Gentry et al., 1988). The amino-terminal portion 
of the pro-form of TGF-/3 is cleaved from the mature carboxy-
terminal 25 KDa dimer by mild proteolysis at a dibasic 
cleavage site (Derynck et a%. , 1985; Gentry et aJ.. , 1988; 
Lyons et , 1990) . The latent complex is not activated 
until the amino-terminal peptide dissociates from the mature 
TGF-)3. Final dissociation of the mature peptide from the 
amino-terminal portion follows treatment with chaotrophic 
agents or pH extremes (Lyons et al.., 1990). Three high 
affinity receptors have been found for TGF-)9. They are types 
I, II and III at 65, 85 and 280 KDa, respectively. Types I 
and II have been recently cloned and are found to contain 
potential serine/threonine kinase domains (Massaguè et al.. 
1992) . The type III receptor is better characterized and is 
the membrane and ECM associated proteoglycan, betaglycan, 
mentioned previously. Latent TGF-)9 may be associated with 
betaglycan in the ECM (Andres et ^ ., 1989). Thus, plasmin 
could both release TGF-/3 from the ECM and activate the latent 
form. 
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SECTION I. 
THE PURIFICATION AND CHARACTERIZATION OF MATRIXIN, 
A PLASMIN RELEASABLE GROWTH INHIBITOR ASSOCIATED 
WITH THE EXTRACELLULAR MATRIX 
14 
ABSTRACT 
Transforming growth factor-beta (TGF-/3) induces the 
production and secretion of type-1 plasminogen activator 
inhibitor (PAI-1) in most cells. PAI-1 is the primary inhib­
itor of plasminogen activator which activates the serine 
protease plasmin. We have examined the effects of plasmin on 
mammalian cell proliferation. We have found that plasmin 
inhibits the proliferation of CCL64 (mink lung epithelial), 
R1B-CCL64 (TGF-/3-receptor mutants of CCL64) , BSC-1 (green 
monkey kidney epithelial) and AKR-2B (mouse fibroblast) cell 
lines. Plasmin inhibits in a dose dependent manner with 7 5-
100% inhibition at 50 mU/ml as measured by ^H-thymidine 
incorporation and labeling indices. The plasmin inhibition 
is abrogated by the serine protease inhibitors aprotinin and 
PMSF indicating proteolysis is required for inhibition. 
Plasmin releases a soluble growth inhibitory factor from the 
extracellular matrix (ECM). The inhibitor, termed matrixin-
A, is not inhibited by the aprotinin or PMSF. Matrixin-A has 
been purified and has a molecular weight of 22 KDa and is not 
TGF-)9. Plasmin does not release TGF-)8 from the extracellular 
matrix even from cells known to secrete large quantities of 
TGF-/3. The material released from plasmin-treated ECM inhib­
its DNA synthesis in R1B-CC164 cells which lack TGF-f3 recep­
tor and fails to induce PAI-1, a gene regulated by TGF-/3, in 
TGF-j8 responsive cells. Plasmin may inhibit mammalian cell 
proliferation by releasing matrixin-A from the ECM. 
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INTRODUCTION 
Extracellular and pericellular proteinases play a major 
role in the regulation of cell proliferation, tissue remodel­
ing, wound healing and differentiation, for reviews see : Dan;b 
et al., 1985; Scott, 1987; Moscatelli and Rifkin, 1988. 
Collagenase (Paranjpe ^  , 1980) , thrombin (Glenn and 
Cunningham, 1979; Keski-Oja et al., 1981), growth-related 
proteinase (Harper et , 1984; Scott and Seow, 1985), 
plasminogen activators (PA) and plasmin (Scott, 1987; Hart 
and Rehemtulla, 1988) are notable examples of proteolytic 
enzymes capable of regulating cell proliferation. Of partie 
ular interest is the plasminogen activation cascade in normal 
and tumorigenic cell growth. The activation of plasminogen 
to plasmin by plasminogen activator is a key step in vascular 
fibrinolysis and wound healing. Plasminogen activation is 
also thought to play a major role in normal tissue remodeling 
and is a characteristic feature upon transformation of cells 
in tumorigenesis (reviewed in Dan0 et al., 1985; Goldfarb and 
Liotta, 1986). Many tumor cell lines have increased PA 
expression compared to normal cells. This increased 
expression is correlated with increased metastatic potential 
(Fulton et aJL., 1982) and is not necessarily correlated with 
the transformation process. 
Plasmin has been proposed as a possible physiologic 
activator of growth factors associated with the extracellular 
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matrix. Basic fibroblast growth factor secreted by bovine 
endothelial cells is sequestered to the ECM of these cells. 
Plasmin and plasminogen activators release bFGF complexed to 
heparan sulfate proteoglycan (Saksela and Rifkin, 1990). 
Furthermore, heparin and heparan sulfate have long been known 
to inhibit proliferation (Castillot et al., 1982; Ishihara et 
al. . 1987). Latent transforming growth factor-j0 is also 
activated by plasmin cleavage (Lyons et , 1988 and 1990). 
One of the recently characterized TGF-jS receptors, betagly-
can, is an ECM associated proteoglycan (Andres et al., 1989). 
Thus plasmin may play a major role in the physiologic activa­
tion of both growth stimulator and growth inhibitors asso­
ciated with the ECM. The ECM would provide a 'milieu' in 
which growth factors could be stored and concentrated to be 
later presented to cells in a finely regulated manner by 
local proteolytic action. 
The link between plasmin and latent TGF-/3 is further 
strengthened by the fact that one of the primary responses of 
most cells in culture in response to TGF-p is the production 
and secretion of type-1 plasminogen activator inhibitor, PAI-
1 (Nilsen-Hamilton and Holley, 1983; Thalacker and Nilsen-
Hamilton, 1987; Laiho et , 1986). It has been proposed 
that PAI-1 feedback inhibits the plasminogen activation 
cascade preventing plasminogen activation which in turn 
prevents further activation of latent TGF-)9 (Lyon et , 
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1988) . This scheme would provide fine tuned regulation of 
both TGF-/3 and plasmin activity. 
While studying TGF-/3 mediated induction of PAI-l we 
found that low levels of plasmin (10 to 50 mU/ml) activity 
inhibited the proliferation of several cell types including 
CCL64 (mink lung epithelial), R1B-CCL64 (TGF-^ receptor 
mutants of CCL64), BSC-1 (green monkey kidney epithelial) and 
AKR-2B (mouse fibroid). The possibility existed that plasmin 
released or activated latent TGF-/3 from the medium, cell 
surface or extracellular matrix. However we have found that, 
at these low plasmin concentrations TGF-)9 is neither 
activated nor released but that another growth inhibitor is 
released from the extracellular matrix. We named this 
inhibitor matrixin-A (matrix inhibitor). Matrixin-A is 
proteolytically released from the ECM of the cell lines 
tested. In this paper we report the purification and 
characterization of this novel growth inhibitor. We propose 
that low levels of proteolytic activity can release matrixin-
A from the ECM which in turn inhibits proliferation of cells. 
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MATERIALS AND METHODS 
Materials 
All reagents and chemicals were purchased from Sigma 
Chemical Co. (St. Louis, MO). and were of reagent grade or 
better. Human plasmin and porcine plasmin was purchased from 
Sigma or Calbiochem (San Diego, CA). One unit of plasmin is 
defined as the amount of enzyme that will hydrolyze 1 /jmol of 
tosyl-Gly-Pro-Lys-PNA per minute at 25°C, pH 7.8. Epidermal 
growth factor was obtained from Collaborative Research 
(Bedford, MS). Human type-1 TGF-0 was purchased from R&D 
Systems (Minneapolis, MN). Type I bovine collagen, human 
placental collagen, fibronectin and heparin were purchased 
from Sigma. Stock dilutions of collagens were prepared by 
dissolution in 25 mM acetic acid. 
Cell Culture and Isolation of the 
Extracellular Matrix 
The TGF-/3 receptor mutant CCL64 cells (Boyd and 
Massaguè, 1989) were a gift from Dr. Joan Massaguè (Sloan 
Kettering Cancer Center, New York, NY). The CCL64 and BSC-1 
cells were a gift from Dr. Robert Holley (Salk Institute, 
Anaheim, CA) and the AKR-2B cells were from Dr. Harold Moses 
(Vanderbilt University, Nashville,TN). All cell types were 
serially propagated every 4 to 5 days in Dulbecco-Vogt's 
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modified Eagle's medium (DMEM) containing 0.45% glucose, and 
with 10% calf serum, 10 units/ml penicillin and lo^g/ml 
streptomycin. 
Isolation of the ECM was performed according to Saksela 
and Rifkin, 1990. Briefly, 2 cm diameter culture wells or 15 
cm diameter culture dishes of confluent cells were washed 
twice with cold TBS (0.14 M NaCl, 5.0 M KCl, 0.68 mM CaClg, 
0.7 mM NagHPO^, 0.5 mM MgClg, 25 mM Tris-HCl, pH 7.4) and 
treated with 0.5% Triton X-100 in 10 mM tris-HCl buffer, pH 
7.4 for 30 minutes at 4°C with gentle rocking. The solution 
was decanted and the dish surfaces were gently rinsed three 
times with cold isotonic-saline. Fifty mUnits/ml plasmin in 
DMEM or TD (TBS without MgCl2 and CaCl2) was added to the 
dishes for one hour at 37°C with rocking, after which 1.0 
Unit/ml aprotinin and or 0.1 mM PMSF was added for another 3 0 
minutes. The medium was removed and spun at 10,000g for 30 
minutes to remove insoluble components. The preparation was 
assayed for growth inhibitory activity or lyophilized and 
equilibrated in 1.0 M acetic acid prior to purification. 
Size Exclusion Chromatography 
The crude matrixin-A from six 15 cm dishes was lyophil­
ized, resuspended in 2.0 ml 1 M acetic acid and loaded on a 1 
X 100 cm Biogel P-60 acrylamide (Biorad Laboratories, Mel­
ville, NY.) column equilibrated with 1 M acetic acid. The 
proteins were eluted with 1 M acetic acid in eighty fractions 
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at 3.0 ml per fraction at a flow rate of 0.25 ml/minute. A 
sample (1.0 /il) of each fraction was assayed on both CCL64 
and R1B-CCL64 cells for inhibition of ^H-thymidine incorpora­
tion as a measure of inhibition of proliferation. Matrixin-A 
activity was identified as the inhibitory fraction that 
inhibited CCL64 and RlB-CCl 64 cells. Fractions that con­
tained matrixin-A were pooled, lyophilized and resuspended in 
1.0 ml HgO with 0.1% trifluoroacetic acid for further purifi­
cation. 
Reverse Phase HPLC 
The pooled Biogel P-60 fractions were loaded in 2 to 3 
injections onto a 3 cm, C-8 reverse phase column (Rainin 
RP300 bondpak, Rainin Instruments Woburn, MA). All buffers 
contain 0.1% TFA. The column was first washed with 6.0 ml of 
HgO. A 50 ml gradient of water and acetonitrile, increasing 
acetonitrile concentration at 1% per minute for 30 minutes, 
followed by 0.75% per minute for 20 minutes was used to 
separate the proteins. The flow rate was 1.0 ml per minute 
and 1.0 ml fractions were collected. Protein was detected by 
spectrophotometry at 220 nm. Protein peaks were separated, 
immediately lyophilized and resuspended in either water or 
0.5 M acetic acid. 
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Bioassay of Growth Inhibitory Activity 
CCL64 and R1B-CCL64 were plated on glass coverslips at 5 
X 10^ cells/well in 24 well tissue culture plates in 1.0 ml 
of the above medium. The cells were grown overnight at 37°C 
in 10% COg after which the medium was changed to 400 iil of 
the above but with only 0.2% calf serum. One microliter of 
each sample was added to wells in triplicate and incubated 
20 hours followed by a 4 hour label with 5.0 juCi/ml ^H-
thymidine which was added directly to the wells. 
The cells on the coverslips were fixed overnight in 
formoline-saline (3.7% formalin, 87 mM NaCl, 107 mM NagSO^), 
washed with 10% trichloroacetic acid for 3 0 minutes at 4°C, 
rinsed with 95% ethanol and removed from the wells to scin­
tillation vials to determine total ^ H-thymidine uptake as a 
measure of DNA synthesis. The mitotic labeling indices that 
reflect the proportion of the cells undergoing DNA synthesis 
were determined after attaching the coverslips to microscope 
slides using Permount (Fischer, Itasca, IL.) and dipping them 
in Kodak nuclear track emulsion (Eastman Kodak, Rochester, 
NY). The slides were allowed to dry and exposed in the dark 
for 2 to 3 weeks after which they were developed. 
Proliferating cells that incorporated ^H-thymidine into 
their DNA exposed the film emulsion resulting in darkened 
nuclei. The total number of cells with darkened nuclei in a 
specific field of the coverslip was divided by the total 
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number of cells in same field. A minimum of 1000 cells in at 
least 6 randomly chosen fields were counted. To enhance cell 
structure the cells were counter stained with Giemsa stain. 
SDS-Polyacrylamide Gel Electrophoresis 
The Bio-gel P-60 fractions were analyzed by SDS-PAGE 
through a 20% homogeneous gel (Phastgel, Pharmacia LKB, 
Piscataway, NY.) with /3-mercaptoethanol to determine the 
degree of purification. The purified matrixin-A from the 
RPLC was also resolved on a 7.5-15% SDS-PAGE (Nilsen-Hamilton 
and Hamilton, 1987) with and without )3-mercaptoethanol to 
determine homogeneity. The gel was stained using a combina­
tion of Coomasie blue-R followed by silver staining. 
Metabolic Labeling of Secreted Proteins 
with ^®S-methionine 
The method of metabolic labeling of secreted proteins 
with 35g_methionine has described in detail in prior publica­
tions (Thalacker and Nilsen-Hamilton, 1987; Nilsen-Hamilton 
and Hamilton, 1987). Briefly, cells were plated 24 well 
tissue culture dishes in DMEM containing 10% calf serum. 
After one day the medium was changed to 0.5% calf serum for 
one more day. The medium was then removed and fresh, serum 
free DMEM with 10% the normal methionine content was added 
containing either 50 mU/ml plasmin with and without 1.0 mU/ml 
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aprotinin, with aprotinin alone or 1.0 ng/ml human TGF-/0. 
After a two hour incubation, 100 /iCi/ml of ^^S-methionine was 
added for a four hour labeling period. The labeled 
conditioned medium was decanted and the proteins resolved on 
a SDS-PAGE followed by fluorography. 
Protein Synthesis Assay 
CCL64 cells were plated on coverslips in 24 well dishes 
in DMEM plus 10% calf serum as described previously. Cells 
were grown for 24 hours, the medium was removed and replaced 
with serum free DMEM containing 10% the normal methionine 
content. Additions, defined in the figure legends, were made 
at this time. After a 20 minute incubation trans-labeled 
^^S-methionine/cysteine was added for forty minutes or 5.5 
hours. The cells on the coverslips were fixed overnight in 
formoline-saline, washed with 10% trichloroacetic acid for 30 
minutes at 4°C, rinsed with 95% ethanol and removed from the 
wells to scintillation vials to determine total TCA precip-
itable counts of ^^S-methionine/cysteine. 
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RESULTS 
Plasmin Mediated Inhibition of DNA Synthesis in CCL64, RiB-
CCL64, BSC-1 and AKR-2B Cells 
The serine protease plasmin inhibits ^H-thymidine incor­
poration in CCL64 cells in dose dependent manner (Figure lA). 
Maximal inhibition occurs at 40 to 100 mU/ml of plasmin as 
compared to controls. The plasmin inhibition of ^H-thymidine 
is mirrored by a similar decrease in the labeling index. The 
decrease results in a 70 to 100% inhibition of DNA synthesis. 
The decrease in labeling index indicates that the plasmin 
effect inhibits DNA synthesis and is not due to cell loss, 
repair DNA synthesis or a decrease in ^H-thymidine uptake. 
The effect of plasmin in not cell type dependent or 
specific to epithelial cells. Plasmin mediated inhibition of 
DNA synthesis was also observed in BSC-1, R1B-CCL64 and AKR-
2B cells (Figure IB). CCL64, R1B-CCL64 and BSC-1 cells are 
the most sensitive to plasmin responding with 50% inhibition 
at 5 to 20mU/ml. The AKR-2B cells are the least responsive 
to the inhibitory effect showing maximal inhibition only at 
100 mU/ml. R1B-CCL64 cells do not respond to the growth 
inhibitory effects of TGF-jS. The responsiveness of R1B-CCL64 
cells to plasmin indicates that the plasmin mediated inhibi­
tion is not due to TGF-jS. Each experiment was performed at 
least twice with three samples at each point. 
Figure l. Plasmin inhibits DMA Synthesis in CCL64/ R1B-CCL64 
BSC-l and AKR-2B cells 
Plasmin at various concentrations in DMEM was added to 
growing CCL64 cells, R1B-CCL64, BSC-l and AKR-2B cells. After 
20 hours the cells were labeled for 4 hours with ^H-thymidine 
as described in the methods. Total TCA precipitable counts 
and the labeling index were measured and normalized to con­
trol cells that received only solvent. Each point is the 
average of three trials. A: ^H-thymidine incorporation (3H-
TdR, shaded) and the labeling index (LI, hatched) for CCL64 
cells at various concentrations of plasmin. B: ^H-thymidine 
incorporation for R1B-CCL64 (black), BSC-l (hatched) and AKR-
2B (dotted). Each experiment has been repeated at least 
twice. 
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Plasmin Mediated Release of a Soluble Growth Inhibitor 
from the Extracellular Matrix 
The ECM of a confluent plate of CCL64 cells was treated 
with and without 50 mU/ml of plasmin generating two ECM 
extracts. The extracts were added to growing CCL64 cells and 
^H-thymidine incorporation was determined to detect the 
presence of plasmin releasable growth factors (Figure 2). 
Plasmin-treated ECM extract inhibited ^H-thymidine 
incorporation 60 to 75% over untreated ECM extract. If 
plasmin at 50 mU/ml was added in conjunction with untreated 
ECM extract the result was significant inhibition. 
Pretreatment of plasmin with either 1.0 U/ml aprotinin or 0.1 
mM PMSF, both serine protease inhibitors, abrogated the 
plasmin mediated inhibition indicating that proteolysis is 
necessary for growth inhibition. 
Plasmin treated ECM extract was incubated with aprotinin 
and or PMSF to inhibit residual plasmin activity. The treat­
ed conditioned medium was still able to inhibit proliferation 
indicating that the soluble growth inhibitory factor was 
released from the ECM by proteolytic action of plasmin and is 
itself not a serine protease. If aprotinin and PMSF were 
added to untreated ECM there was no significant effect on 
thymidine incorporation indicating that neither of these 
protease inhibitors affects proliferation at the concentra­
tions used in the bioassay. We named this plasmin-released 
factor, matrixin-A. 
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Identification and Purification of Matrixin-A 
The plasmin releasable growth inhibitory factor can be 
isolated from the ECM of both BSC-1 and CCL64 cells. Concen­
trated plasmin treated ECM from both BSC-1 (Figure 3A and 3C) 
and CCL64 cells (Figure 3B) was separated on a Biogel P-60 
size exclusion column. Fractions from BSC-1 derived ECM were 
assayed using both CCL64 (Figure 3A) and R1B-CCL64 cells 
(Figure 3B) in the bioassay. The growth inhibitory activity 
eluted similarly for the BSC-1 cell derived and CCL64 cell 
derived matrixin-A. The peak of matrixin-A activity eluted 
very close to the phenol red from the medium. Phenol red is 
the major A^SO'^bsorbing peak on the column. The matrixin-A 
elution profile corresponded with the elution of the myoglo­
bin standard indicating a molecular weight at approximately 
18 KDa. The matrixin-A from both BSC-1 cells (Figure 3C) and 
CCL64 cells (data not shown) inhibited R1B-CCL64 cells indi­
cating that the inhibition was not mediated by TGF-jS. 
Figure 2. Plasmin releases a soluble growth inhibitor form 
the extracellular matrix 
CCL64 cells grown in 24 well culture dishes were removed 
from their ECM as described in the methods. The ECM was 
treated with and without plasmin at 50 mU/ml for 1 hour at 
37°C in serum-free DMEM. The ECM was removed and added to 
growing CCL64 cells with the following additions; 1) Plas­
min at 50 mU/ml (PL); 2) Plasmin premixed with 1 U/ml aprot-
inin (PL:AP) or 0.1 mM PMSF (PL:PM); 3) aprotinin (AP); 4) 
PMSF (PM); 5) 5.0 ng/ml EGF (E); and 6) 1.0 ng/ml TGF-p (T). 
Control ECM, solid box; Plasmin treated ECM (hatched box). 
The ^H-thymidine incorporation was determined. All values 
were normalized to untreated ECM that received only solvent. 
Each treatment is the average of three trials. 
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Figure 3. Matrixin from both CCL64 and BSC-1 cells is semi-
purified by a Biogel P-60 column and assayed in 
CCL64 and R1B-CCL64 cells for growth inhibitory 
activity 
Plasmin treated ECM from six 15 cm tissue culture dishes 
of both BSC-1 (A and B) and CCL64 (C) was isolated and puri­
fied by size exclusion chromatography using Biogel P-60 and a 
buffer of 1 M acetic acid. Fractions of 3.5 ml were collect­
ed. Ten microliters of each fraction was assayed for growth 
inhibitory activity of CCL64 cells (A and C) and R1B-CCL64 
(B) as determined by ^H-thymidine incorporation (solid line). 
Each point is the average of three trials and is represented 
as fold/control which is the total TCA precipitable counts of 
each fraction normalized to the first collected fraction. 
The absorbance at 280 nm was monitored (dotted line). The 
markers ( | | ) indicate the migration of BSA (67 KDa) 
and myoglobin (18 KDa) standards, respectively. 
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The Biogel P-60 column fractions of CCL64 derived mat-
rixin-A were run on a 20% non-reducing SDS-PAGE to identify 
proteins (Figure 4). Two major protein bands at 17 KDa and 
5 KDa co-elute with the inhibitory activity. Further 
purification by RPLC was performed on a C-8 column eluted 
with a gradient of acetonitrile (Figure 5). 
The fractions were assayed on R1B-CCL64 cells and indi­
cates growth inhibitory activity in fractions 2-4 and 25. 
The fraction 3 peak elutes in water indicating a hydrophilic 
factor. Fraction 25 inhibitory activity elutes at 47% aceto­
nitrile indicating a hydrophobic factor. These fractions 
were separated on a 7.5-15% SDS-PAGE with and without reduc­
tion and stained using a combination of Coomasie-blue and 
silver stain (Figure 6). The fraction 25 growth inhibitor 
contained a protein of approximately 20 KDa that co-eluted 
with the inhibitory activity. The protein migrated at the 
same rate with and without reduction suggesting a monomeric 
structure. Fraction 3 does not contain any identifiable 
proteins. The growth inhibitory effect of this fraction may 
be the result of salt effects or of a small hydrophilic non-
proteinaceous inhibitory substance. The high molecular band 
is a staining artifact and is probably contaminating kera­
tins from the )3-mercaptoethanol used as a reducing agent for 
gel electrophoresis. 
Figure 4. SDS-FA6E of Biogel P-60 purified matrixin from the 
ECM of CCL64 cells 
Ten microliters of fractions 47-72 from the plasmin 
treated ECM of CCL64 cells were lyophilized and separated on 
a 2 0% SDS-PAGE without reduction and visualized by combina­
tion staining using Coomasie blue-R and silver staining. 
Apparent molecular weights were determined by running stand­
ard proteins at the same time. The fractionated proteins are 
compared to the proteins in crude concentrated CM from ECM 
treated with (PL) and without (-) plasmin. Matrixin activity 
is found in fractions 50-65 and corresponds to major protein 
bands at 5 and 17 KDa. 
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Figure 5. Further purification of CCL64 derived matrixin by 
reverse phase HPLC 
Fractions from the Biogel P-60 column that contain 
matrixin from CCL64 cells were pooled, lyophilized and resus-
pended in water containing 0.1% TFA. The matrixin was sepa­
rated on C-8 reverse phase column and eluted with a gradient 
of water and acetonitrile containing 0.1% TFA as described in 
the methods. Fractions of 1.5 ml were collected, lyophilized 
and resuspended in 20 microliters of 0.5 M HOAc. One micro­
liter of each fraction was assayed in R1B-CCL64 cells for 
matrixin activity. Two peaks of growth inhibition were found 
one in the void fractions (2-4) and another at 47% acetoni­
trile (fraction 25) as measured the ^H-thymidine incorpora­
tion assay described in methods. 
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Figure 6. SDS-PAGE of RPLC purified CCL64 derived 
matrixin-A 
One microliter of the concentrated C-8 RPLC peaks con­
taining matrixin in figure 6 were separated on both reducing 
and non-reducing 7.5-15% SDS-PAGE and stained using both 
Coomasie blue-R and silver staining. A 20 KDa protein is 
found in fraction 25 with and without /3-mercaptoethanol 
(- red.). Fraction 25 correlates with the growth inhibitory 
activity and is defined as matrixin-A. The first growth 
inhibitor peak, exemplified by fraction #3, contained no 
resolvable protein. 
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Matrixin-A is not TGF-/3 
The plasmin releasable growth inhibitor inhibits RIB-
CCL64 cells as indicated in Figure 3C. These mutants do not 
express TGF-/3 receptor and are not growth inhibited by TGF-/3. 
Furthermore TGF-p migrates at approximately 32% rather than 
47% acetonitrile in the same type of RPLC gradient 
(manuscript in preparation). 
It was also reasoned that if the plasmin releasable 
factor was TGF-)3 then cells should respond to this factor by 
expressing TGF-/3 responsive genes. One good TGF-^ inducible 
marker is type-1 plasminogen activator inhibitor (PAI-1). 
The induction of PAI-1 is very sensitive to TGF-j3, at least 
equal to or greater than TGF-)3 mediated inhibition of DNA 
synthesis. One can monitor PAI-1 expression by examining the 
production and secretion of ^^S-methionine labeled protein by 
responsive cells. Plasmin does not induce PAI-1 expression 
whereas PAI-1 was induced by TGF-)9 (Figure 7) . 
Several protein bands that do not correspond to PAI-1 at 
35, 30 and 22 KDa are resolved. These proteins are either 
the proteolytic breakdown products of higher molecular weight 
proteins or plasmin inducible proteins. The appearance of 
these bands depends upon proteolysis because pretreatment of 
plasmin with aprotinin prevents their appearance. 
Several ECU proteins were tested for growth inhibitory 
activity using the bioassay. Neither fibronectin, type 1 
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collagen, placental collagen nor heparin inhibited CCL64 
cells (Figure 8). These ECM proteins were added to growing 
CCL64 cells at various concentrations. No significant growth 
inhibition was found at 1 to 100 ug/ml for each protein. If 
type 1 collagen is pretreated with plasmin at 50 mU/ml fol­
lowed by inhibition of residual proteolytic activity by 
aprotinin and PMSF matrixin-A like growth inhibitory activity 
was found (Figure 9). 
Figure 7. Plasmin does not induce PAI-1 in CCL64 cells 
Growth factor related induction of plasminogen activator 
inhibitor type 1 (PAI-1) was monitored by examining the 
secretion of ^^S-methionine labeled proteins by CCL64 cells 
following the addition of 50 mU/ml plasmin (PL), 1 U/ml 
aprotinin (AP) and combined plasmin and aprotinin (PL/AP). A 
positive control of 1.0 ng/ml TGF-)3 was performed to show 
PAI-1 induction. PAI-1 migrates at 48 KDa. A control sample 
of cells treated with solvent (-) was also performed. The 
above additions were given to growing CCL64 cells in 24 well 
dishes containing DMEM with 10% of normal methionine. A 
preincubation of 2 hours with the described treatment was 
followed by a 4 hour label with 100 /iCi/ml of ^^S-methionine. 
The labeled conditioned medium was isolated and separated on 
a 7.5-15% reducing SDS-PAGE. Labeled proteins in the gel 
were resolved by fluorography. 
43 
a. 
? 
- PI AP s; TGF-b 
Figure 8. Effect of various ECM proteins of proliferation of 
CCL64 cells 
Various extracellular matrix associated proteins were 
added to growing CCL64 cells. Fibronectin (FB, +); human 
placental collagen (CL H.pl, •)/ type I bovine collagen (CL, 
-) ; and heparin (HEP, *•) at concentrations of 1, 10, 25, 50 
or 100 ug/ml were added to growing CCL64 cells and labeled 
with ^H-thymidine as described previously. The collagens 
were dissolved in 250 mM acetic acid and the other proteins 
in DMEM. The final concentration of acetic acid was in all 
samples 2.5 mM. Total TCA precipitable counts were normalized 
to control cells that received only solvent. Each point is 
the average of three samples. 
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Figure 9. Plasmin releases growth inhibitory activity from 
type-1 collagen 
Bovine type-1 collagen treated with and without plasmin 
was added to growing CCL64 cells. Bovine type-1 collagen at 
10 ug/ml in DMEM was treated with (CL/PL) and without (CL) 
plasmin at 50 mU/ml for 3 hour at 37° followed by addition of 
O.litiM PMSF and 1 unit/ml aprotinin for 1 hour at 37°. Sam­
ples were added to growing CCL64 cells and labeled with ^H-
thymidine as described in the methods. Total TCA precipita-
ble counts were normalized to control cells that received 
only solvent. Each point is the average of three samples. 
Transforming growth factor-^ (TGF-beta) at 1.0 ng/ml was 
added as a positive control. 
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Matrixin-A Does Not Inhibit Protein Synthesis or 
Mitogen Induced Protein Synthesis 
Extracellular matrix extract derived from CCL64 cells treated v/i 
and without plasmin does not inhibit protein synthesis of 
CCL64 cells after six hours (Figure lOA). The induction of 
protein synthesis by the mitogens EGF, PMA, and calf serum 
and the growth inhibitor TGF-p was not abrogated by the 
addition of ECM treated with and without plasmin (Figure 
lOA). Purified matrixin-A at levels that inhibit ^H-thymi-
dine incorporation did not inhibit protein synthesis measured 
at one hour after addition (Figure lOB). 
Figure 10. Matrixin-A does not inhibit protein synthesis in 
CCL64 cells 
A: CCL64 cells grown in 24 well culture dishes were removed 
from their ECM as described in the methods. The ECM was 
treated with (hatched: ECM+PL) and without plasmin (dotted: 
ECM-PL) at 50 mU/ml for 1 hour at 37°C in serum-free DMEM 
followed by treatment with O.lmM PMSF and 1.0 U/ml aprotinin. 
A control sample containing only solvent without ECM extract 
was treated identically (cross-hatched: CONTROL). Samples of 
each were added to growing CCL64 cells with the following 
additions: -, solvent; E, epidermal growth factor at 25 
ng/ml; P, phorbol myristate acetate at 10 ng/ml; T, Trans­
forming growth factor-# at 0.3 ng/ml; CS, calf serum at 2.5%. 
The cells were incubated for 20 minutes followed by a 5.5 
hour label with 15 /liCi/ml trans-labeled ^^S methionine/cys­
teine. Each treatment was done in triplicate. 
B: Purified matrixin-A and TGF-/3 (0.3 ng/ml) was added 
to growing CCL64 cells for 20 minutes followed by a 40 minute 
labeling with 7.8 ^Ci/ml trans-labeled methionine/cys­
teine. Eight trials were performed for each treatment. 
The average total TCA precipitable cpm were determined. All 
values were normalized to control that received only solvent. 
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DISCUSSION 
There exists a strong tie between extracellular proteo­
lytic activity and secreted growth factors. Proteinases are 
capable of activating latent growth factors and releasing 
growth factors from the extracellular matrix (ECM). Basic 
fibroblast growth factor, heparin, sialoglycoprotein and TGF-
13 are examples of factors that can be released by proteolysis 
(for review, Ruoslahti, 1989). Basic fibroblast growth factor 
(FGF) secreted by bovine endothelial cells is found bound to 
heparan sulfate proteoglycan (HSPG) complexes in the ECM 
(Saksela and Rifkin, 1990). The bFGF-HSPG is released from 
the ECM upon treatment with plasmin. The inactive precursor 
plasminogen can also release bFGF-HSPG from cell cultures and 
this activity is enhanced upon the addition of exogenous 
plasminogen activators. Saksela and Rifkin (199 0) proposed 
that the mechanism for the release of biologically active 
FGF is through the plasminogen activation cascade and the 
regulation of the release is dependent upon factors that 
affect the proteolytic environment of the ECM. 
Matrixin-A is a growth inhibitor released from the ECM. 
Its activity is evident in cultured cells treated with plas­
min. Plasmin inhibits DNA synthesis in both epithelial and 
fibroblast cells in a dose dependent manner with maximal 
inhibition at 50 to 100 mU/ml of plasmin activity. The 
inhibition is abrogated if the plasmin is pretreated by 
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serine protease inhibitors indicating the requirement prote­
olysis for release of the growth inhibitory activity. We were 
able to cause the proteolytic release of this soluble growth 
inhibitor from the ECM of both CCL64 and BSC-1 cells. The 
release may not be plasmin specific as low concentrations of 
trypsin could also release a growth inhibitory activity (data 
not shown). In these studies plasmin was used as the releas­
ing agent because of its physiological prevalence. 
Extracellular matrix treated with plasmin and purified 
matrixin-A at concentrations that inhibit ^H-thymidine incor­
poration did not inhibit protein synthesis. Nor did ECM 
treated with plasmin inhibit mitogen induced protein synthe­
sis indicating that the plasmin releasable matrixin-A is not 
acting to inhibit ^H-thymidine incorporation by inhibiting 
protein synthesis. 
Purification of the plasmin released growth inhibitor 
resulted in the isolation of a 22 KDa acid stable single 
chain protein with a relativly high hydrophobicity. In lieu 
of a peptide sequence several potential candidates have been 
tested for growth inhibitory activity similar to matrixin-A. 
Two candidates are TGF-j0 and sialoglycoprotein due to their 
growth inhibitory activity and size. 
Transforming growth factor beta (TGF-p) can both inhibit 
and stimulate cell proliferation, mediate differentiation and 
is chemotaxic (for reviews see: Sporn et , 1987; Massaguè, 
1990; Moses et al., 1990; Nilsen-Hamilton, 1990). It is 
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produced and secreted by many cell types as a latent dimer 
consisting of two disulfide linked monomers of 3 61 amino acid 
residues (Derynck et al., 1985; Gentry et , 1988). The 
amino-terminal portion of the pro-form of TGF-jS is cleaved 
from the mature carboxy-terminal 25 KDa dimer by proteolysis 
at a dibasic cleavage site (Derynck et , 1985; Gentry et 
al.. 1988; Lyons et al., 1990). The latent complex is not 
activated until the amino-terminal peptide dissociates from 
the mature TGF-p. Final dissociation of the mature peptide 
from the amino-terminal portion follows treatment with chao-
trophic agents, pH extremes or futther proteolysis (Lyons et 
al., 1990) . Latent TGF-)8 may be associated with betaglycan 
in the ECM (Andres et ^ ., 1989). Thus, plasmin could both 
release TGF-/3 from the ECM and activate the latent form. 
Plasmin has been proposed as the physiologically activa­
tor of latent TGF-# (Lyons et al., 1990; Sato and Rifkin, 
1989). Bovine pericytes and smooth muscle cells can inhibit 
migration of bovine endothelial cells in co-culture presuma­
bly by their production of plasmin that activates latent TGF-
P secreted by the cells (Sato and Rifkin, 1989). Latent TGF-
P seems to exist in two pools, one activated by plasmin at 
300 to 1000 mU/ml or pH 4.5, and another activated by extreme 
pH 1-2. 
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Several points of evidence indicate that matrixin-A is 
not TGF-/?. The first is that the TGF-)0 receptor mutant cells 
R1B-CCL64 are inhibited by matrixin-A. These mutants were 
isolated from a population of mutagenized CCL64 cells that 
failed to express the 53 KDa TGF-/3 receptor. They are nei­
ther growth inhibited by TGF-^ nor respond to TGF-/Î by pro­
ducing fibronectin (Boyd and Massaguè, 1989). By using these 
cells TGF-p can be definitively distinguished from other 
growth factors. The plasmin releasable growth inhibitory 
activity also fails to induce plasminogen activator inhibitor 
type-l in CCL64 cells. CCL64 cells are highly sensitive to 
TGF-J0 and respond to it by producing large quantities of PAI-
1 (Thalacker and Nilsen-Hamilton, 1987). If plasmin were 
releasing TGF-# there should be induction of PAI-1 in CCL64 
cells treated with plasmin. Also there was no significant 
activation of TGF-j0 at below 100 mU/ml plasmin (Lyons et , 
1988 and 1990). In this study optimal release of growth 
inhibitory activity from the ECM occurred with 50 mU/ml of 
plasmin. This result also suggests that this plasmin-
generated inhibition observed in this study was not due to 
activation of ECM-bound latent TGF-jS. 
Finally, the purified matrixin-A fails to disassociate 
upon reduction whereas TGF-)9 dissociates readily into its 
monomeric form at 12.5 KDa. Matrixin-A also migrates differ­
ently on a C-8 reverse phase column and elutes at 47% as 
opposed to 32% for TGF-/3. 
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Sialoglycoprotein is another candidate for matrixin-A 
due to size and growth inhibitory activity. Sialoglycopro­
tein is a 18 KDa protein that reversibly inhibits protein and 
DNA synthesis in normal 3T3 cells (Sharifi et a%.^ 1986). It 
is found associated with the cell surface of bovine cerebral 
cortex cells and is released by mild proteolysis using pro-
nase. Inhibition of protein synthesis by sialoglycoprotein 
in 3T3 cells occurs within one hour following addition. 
Purified matrixin-A was unable to inhibit protein synthesis 
at one hour in CCL64 cells indicating that matrixin-A is 
possibly not sialoglycoprotein. 
Several other ECM related proteins were tested for 
growth inhibitory activity. Neither heparin, type-1 colla­
gen, placental collagen nor fibronectin inhibited DNA synthe­
sis in the bioassay. We had reason to believe that type-1 
collagen may inhibit DNA synthesis as it is a proposed media­
tor of growth inhibition in NRK cells. Nugent and Newman 
(1989) found that TGF-j3 induces collagen and that the colla­
gen inhibits proliferation. Although collagen is not a 
substrate for plasmin, plasmin can activate latent collage-
nase which in turn could release collagen fragments. We have 
found that treatment of type-1 collagen preparations with 
plasmin also results in the release of growth inhibitory 
activity that resembles that released from the ECM. Collagen 
fragments generated by activation of collagenases may be 
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inhibiting proliferation or the collagen preparation may be 
contaminated with a matrixin-A type factor that can be re­
leased by proteolysis. 
The release of matrixin-A by plasmin may be a mechanism 
that prevents cells from uncontrolled growth and metastasis. 
Tsuboi and Rifkin (1990) found that the metastatic potential 
of a tumor cell is inversely proportional to the level of 
plasminogen activation as measured by amniotic membrane 
invasion assay. They found that cells that produce high 
levels of plasminogen activator are poorly metastatic while 
those that produce low levels are very invasive. The differ­
ential production of plasminogen activator may result in 
differential levels of plasmin activity. It is possible that 
normal non-transformed cells may also respond to differential 
levels of plasminogen activator. There is the possibility 
that lower concentrations of plasminogen activator are active 
in stimulating local degradation of the ECM by activating 
plasminogen but do not produce enough active plasmin to 
release matrixin-A and at higher concentrations matrixin-A 
can be released resulting in the inhibition of cell prolifer­
ation. 
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SECTION II. 
A HIGH YIELD PURIFICATION AND NOVEL ASSAY FOR 
THE PURIFICATION OF BOVINE PLATELET 
TRANSFORMING GROWTH FACTOR BETA 
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ABSTRACT 
Type-1 transforming growth factor-/? (TGF-jSl) has been 
purified to homogeneity from bovine platelets by using a new 
high yield, two step procedure. TGF-jS mediated growth inhib­
itory activity was assayed using a novel approach in which 
both TGF-/Î responding cells (CCL64) and non-responding cells, 
TGF-^-receptor mutants (R1B-CCL64) were used in a 
^H-thymidine incorporation assay. The assay specifically 
identifies TGF-^ mediated inhibition from other potential 
growth inhibitory activities in platelets. The rapid purifi­
cation procedure includes non-denaturing gel filtration 
followed by reverse phase HPLC of acid/ethanol extracted 
bovine platelets. Yields of 10 /ng of TGF-/31 per gram of 
platelets and specific activities of 1.2 X 10® units/ug were 
obtained. 
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INTRODUCTION 
The TGF-p family of polypeptide growth factors have 
great significance in the regulation of cell growth and dif­
ferentiation. In recent years great strides have been made 
in defining the role of TGF-/3 in cell physiology (for reviews 
see: Nilsen-Hamilton, 1990; Massaguè, 1990). Important to 
this effort is the availability of abundant, highly pure 
TGF-p. TGF-p was originally purified from outdated human 
platelets (Assoaian ^  , 1983) and bovine kidney (Roberts 
et al.. 1983). Platelets are the source of other growth 
regulators including platelet derived growth factor, (PDGF; 
van den Eijnden-van Raaij et al., 1988; Assoian et al., 
1983) . The extracellular matrix of many tissues is found to 
contain fibroblast growth factor, (FGF; Saksela and Hifkin, 
1990) and the growth inhibitor sialoglycoprotein (Bascom et 
al., 1987). It is therefore important that any bioassay used 
in the purificaton of TGF-p, specifically identify HGF-p. 
Past purifications of TGF-/3 use acid/ethanol extraction 
of platelets followed by size exclusion chromatography with 
and without dénaturants, cation exchange chromatography and 
reverse phase liquid chromatography (RPLC) to isolate TGF-p. 
Fractions containing TGF-)3 must be dialyzed to remove salts 
and organic solvents before assaying. More recent protocols 
(Cone et al., 1988) and (van Eijnden-van Raaij et , 1988) 
have eliminated the denaturing size exclusion step and 
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increased yields but the bioassay is still time consuming and 
doesn't eliminate other potential growth factors that mediate 
similar cellular effects. • The classic assays for TGF-jB 
include TGF-J3 mediated colony formation of transformed cells 
(Assoian et al., 1983; Roberts et al., 1980) and inhibition 
of ^H-thymidine incorporation (Cone et al., 1988; Tucker 
et al., 1984) in responsive cell lines. 
We report here a simple, high yield two step purifica­
tion of TGF-^l from bovine platelets that employs a novel 
assay which specifically identifies TGF-/3 and minimizes the 
need for Western blotting, sequencing and or competitive 
inhibition assays to identify TGF-/9 mediated effects. 
63 
MATERIALS AND METHODS 
Materials 
All reagents and chemicals were purchased from Sigma 
Chemical Co. (St. Louis, MO). and were of reagent grade or 
better. Crystalline bovine serum albumin was also from 
Sigma. Human type-1 TGF-0 was purchased from R&D Systems 
(Minneapolis, MN). Fresh bovine blood was obtained from 
local meat packers. 
Acid Ethanol Extraction of Platelets 
Isolation of TGF-/3 from bovine platelets was performed 
using an adaptation of a procedure described previously 
(Assoian et ^ ., 1983). Briefly, 13 liters of fresh bovine 
blood was immediately diluted with 2.5 liters of 2.2% sodium 
citrate, 0.8% citric acid and 2.2% dextrose to prevent clot­
ting. The blood was equilibrated to 4°C and centrifuged at 
aoog for 30 minutes. The platelet rich plasma was decanted 
and spun again a 2200g, 30 minutes at 4°C, to pellet the 
platelets. The pellet was resuspended in 15.3 mM tris pH 
7.5, 135 mM NaCl, 0.31% dextrose, 0.08% citric acid, 0.26% 
sodium citrate and spun at 2200g, 30 minutes at 4°C. The 
platelet pellet was weighed and 4 ml of acidic-ethanol (93% 
ethanol, 230 mM HCl, 1 mM PMSF and 6 juM pepstatin) was added 
per gram of platelets. The mixture was homogenized with a 
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dounce homogenizer on ice and the resultant extract was 
equilibrated over- night at 4°C followed by centrifugation at 
2200g, 30 minutes at 4°C. The supernatant was adjusted to pH 
3.0 with NH4CO3. Two volumes of ethanol and four volumes of 
anhydrous ether were added and the protein component precipi­
tated overnight at 4°C. The protein was pelleted by centrif­
ugation at 2300g for 30 minutes. The pellet was dissolved in 
10 ml 1 M acetic acid and stored at 4°C until further purifi­
cation. The crude TGF-)3 was spun at 2300g 10 minutes prior 
to size exclusion chromatography to remove insoluble precipi­
tates. All samples were assayed by fluorescence spectropho­
tometry to determine total protein concentrations based upon 
a standard curve prepared against bovine serum albumin. 
Size Exclusion Chromatography 
The crude TGF-j3 was lyophilized, resuspended in 2.0 ml 
1 M acetic acid and loaded on a 1 X 100 cm Biogel P-60 acryl-
amide (Biorad Laboratories, Melville, NY.) column equilibrat­
ed with 1 M acetic acid. The proteins were eluted with 1 M 
acetic acid in eighty fractions at 3.0 ml per fraction at a 
flow rate of 0.25 ml/minute. A sample (1.0 /xl) of each frac­
tion was assayed on both CCL64 and R1B-CCL64 cells for inhi­
bition of ^H-thymidine incorporation for a measure of inhibi­
tion of proliferation. TGF-)3 activity was identified as the 
inhibitory fraction that inhibited thymidine incorporation in 
CCL64 but not RlB-CCl 64 cells. Those fractions that con-
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tained TGF-# activity were pooled, lyophilized and resuspend-
ed in 1.0 ml HgO with 0.1% trifluoroacetic acid for further 
purification. 
Reverse Phase HPLC 
The pooled Biogel P-60 fractions were loaded in 2 to 3 
injections onto a 3 cm, C-8 reverse phase column (Rainin 
RP300 bondpak, Rainin Instruments Woburn, MA) and eluted 
under a 50 ml gradient of water and acetonitrile. After a 
6.0 ml wash of H^O, acetonitrile increased at a rate of 1% 
per minute for 24 minutes, followed by 0.75% per minute for 
20 minutes. All buffers contained 0.1% TFA. The flow rate 
was 1.0 ml per minute and 1.5 ml fractions. Protein was 
detected by spectrophotometry at 220 nm. Protein peaks were 
separated, immediately lyophilized and resuspended in either 
4 mM HCl or 4 mM HCl plus 0.1% crystalline BSA. 
Bioassay of TGP-/3 Activity 
Mink lung epithelial cells (CCL64) obtained from the 
American Type Culture Collection and TGF-)9 receptor mutant 
CCL64 cells (Boyd and Massaguè, 1989) from Dr. Joan Massaguè 
(Sloan Kettering Cancer Center, New York, NY) were used to 
assay for TGF-/3 specific growth inhibitory activity. Both 
cell types were serially propagated every 4 to 5 days in 
Dulbecco-Vogt's modified Eagle's medium (DMEM) containing 
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0.45% glucose, 10% calf serum, 10 units/ml penicillin and 
10 ug/ml streptomycin. 
CCL64 and R1B-CCL64 were plated on glass coverslips at 
5 X 10^ cells/well in 24 well tissue culture plates in 1.0 ml 
of the above medium. The cells were grown overnight at 37°C 
in 10% COg after which the medium was changed to 400 /xl of 
the above but with only 0.2% calf serum. One microliter of 
each sample was added to wells in triplicate and incubated 2 0 
hours followed by a 4 hour label with 5.0 ^Ci/ml ^H-thymidine 
which was added directly to the wells. The cells on the 
coverslips were fixed overnight in formol in-saline (3.7% 
formalin, 87 mM NaCl, 107 mM NagSO^) washed with 10% trichlo­
roacetic acid for 30 minutes at 4°C, rinsed with 95% ethanol 
and removed from the wells to scintillation vials to deter­
mine total ^H-thymidine uptake as a measure of DNA synthesis. 
The mitotic labeling indices that reflect the proportion of 
the cells undergoing DNA synthesis were determined by attach­
ing the coverslips to microscope slides using Permount 
(Fischer Inc, Itasca, IL.) and dipping in Kodak nuclear track 
emulsion (Eastman Kodak, Rochester, NY.). The slides were 
allowed to dry and exposed in the dark for 2 to 3 weeks after 
which they were developed. Proliferating cells incorporated 
^H-thymidine into their DNA that exposed the film emulsion 
resulting in darkened nuclei. 
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SDS-Folyacryleunide Gel Electrophoresis 
The purified TGF-/3 wa's run on a 20% homogeneous SDS-PAGE 
(Phastgel, Pharmacia LKB, Piscataway, NY.) with and without 
beta-mercaptoethanol to determine the degree of purification. 
The gel was stained using a combination of Coomasie blue-R 
followed by silver staining. 
Amino Acid Analysis 
The amino analysis of the purified protein was performed 
to estimate the yield of the final purified protein and to 
further demonstrate that the protein is TGF-/3. The analysis 
was performed by the Iowa State University Protein Facility, 
Ames, Iowa. Briefly, 5.0 nl of sample was acid hydrolyzed, 
loaded onto an Applied Biosystems (Foster City, CA) 42OA gas 
phase derivatizer, and separated on a C-18 RPLC under a 
gradient of sodium acetate/acetonitrile. A known amount of 
norleucine was added to the sample as an internal standard. 
Both the amino acid composition and total protein mass can be 
determined. 
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RESULTS 
Past procedures for purification of active TGF-p have 
used platelets as the source material (Cone et al., 1988; 
Assoian et , 1983; Van den Eijnden-van Raaij et al., 
1988). The yields obtained in these procedures have ap­
proached 2 to 20 jLtg of active TGF-/? per unit of outdated 
human platelets. Although human platelets are a good source 
of TGF-/3, problems arise in finding a source, in the cost, 
and the possible contamination by virulent pathogens. We 
therefore set out to purify TGF-# from easily obtained bovine 
platelets. 
The classic bioassays for TGF-)3 are based either on its 
ability to cause soft agar colony growth in AKR-2B or NRK 
cells or its ability to inhibit ^H-thymidine incorporation in 
CCL64. The soft agar assay is slow, laborious and can be 
affected by the presence of other growth factors including 
EGF and TGF-a. Although much faster, the sensitivity of the 
^H-thymidine incorporation assay in CCL64 cells interferes 
with the defining of peaks of activity in column fractions 
(Van den Eijnden-van Raaij et al., 1988). This problem can 
be somewhat offset by concurrent use of SDS-PAGE, to identify 
the position of the protein, but both these assays fail to 
specifically identify TGF-/3 as the effector. One can use 
western blotting or radioimmunoassays to identify TGF-j0 but 
these increase the work and demand the availability of costly 
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antibody to TGF-#. We have developed a simple assay scheme 
for TGF-/3 that specifically defines TGF-j9 mediated activity 
and clearly defines the location of TGF-/3 during purifica­
tion. We have taken advantage of the TGF-/3 receptor mutant 
cell line, R1B-CCL64 which does not respond to TGF-/3 (Boyd 
and Massaguè, 1989) . During the purification of TGF-/3, 
column fractions are assayed in both CCL64 and R1B-CCL64 
concurrently for their ability to inhibit ^H-thymidine incor­
poration (Table 1). Using this assay we developed a rapid 
two step purification that yields high quantities of highly 
active homogeneous TGF-)S. The bioassay has also allowed the 
identification of growth inhibitors that are not TGF-/3, 
namely matrixin-A, an extracellular matrix associated, plas-
min releasable growth inhibitor (manuscript in preparation). 
Platelet Extraction of TGT-(3 
The extraction of platelets was performed using adapta­
tions of previous procedures (Assoian et , 1987). Bovine 
blood was collected. An anticoagulant solution of sodium 
citrate and dextrose was added immediately after collection. 
The platelets were pelleted by centrifugation, washed, ho­
mogenized and resuspended in acidic ethanol. The protein 
fraction was precipitated in ethanol/ether and resuspended in 
1 M acetic acid prior to the size exclusion step. An average 
of 0.65 g of platelets were obtained per liter of bovine 
blood as determined in three platelet preparations. 
Table 1. Human TGP-/J and the purified platelet inhibitor do 
not inhibit R1B-CCL64 cells 
Growing CCL64 and R1B-CCL64 cells were labeled with ^H-
thymidine for four hours following a 20 hour preincubation 
with 10 ng/ml of either human type-1 TGF-)S or purified bovine 
platelet derived growth inhibitor. Each point is the total 
cpm average +/- S.D. of three samples. 
Cell line cpm of 3H-thymidine 
Control hTGF-beta Purified 
(10 ng/ml) Inhibitor 
CCL64 8058 +/- 637 281 +/- 9 332 +/- 32 
R1B-CCL64 5467 +/- 337 4845 +/- 383 5393 +/- 307 
Table 2. The purification table of platelet derived bovine 
TGF-/3 
Bovine platelets were extracted with acidic ethanol and 
the protein was precipitated with ether/ethanol. The ex­
tracted protein was further purified by size exclusion 
chromatography using a Biogel P-60 column followed by a 
reverse phase HPLC on a Brownlee bondpak RP-300 C-8 column. 
For analyzing fractions from the extraction and size exclu­
sion step , total protein was determined by fluorimetry using 
a BSA standard. Total protein was determined using an amino 
acid analysis after reverse phase HPLC. Fractions were 
assayed for the ability to inhibit ^H-thymidine in CCL64 
cells. One unit of TGF-)3 activity is defined as the amount 
per milliliter needed to inhibit 50% of ^H-thymidine incorpo­
ration. 
PURIFICATION OF BOVINE PLATELET TGF-beta 
Purification 
Step 
total 
protein 
recovered 
activity 
(units 
X lOE-8) 
specific 
activity 
(units/ug) 
degree 
of 
purification 
% 
recovery 
Extraction 189 mg 12 6349 1 100 
Bio-Gel P-60 5.25 mg 5 95238 15 42 
HPLC C-8 162 ug 200 120000000 18900 1666 
From 15 g of platelet 
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From 15 grams of platelets we obtained a yield of 189 mg 
of total protein with a specific TGF-/3 activity of 6349 units 
per fig of protein (Table 2) . The definition of a unit is the 
dose at which ^H-thymidine incorporation is inhibited fifty 
percent. The TGF-/3 activity was compared to a standard curve 
prepared against human type 1 TGF-/Î from R&D systems (Min­
neapolis, MN) . 
Size Exclusion Chromatography 
The extracted protein was loaded onto a Biogel P-60 size 
exclusion column and eluted with 1 M acetic acid. Fractions 
were assayed concurrently with both CCL64 and R1B-CCL64 cells 
(Figure lA). The fractions were assayed directly without 
dialysis. DNA synthesis in either cell line is expressed as 
the amount of ^H-thymidine incorportion by the treated cells 
normalized to a control value of incorporation from cells 
treated with solvent only. The relative incorporation can 
also be compared between the cell lines as a response ratio 
(Figure IB) . Specific TGF-/3 mediated inhibitory activity 
characteristically eluted in later fractions due to its 
hydrophobic nature. The degree of purification was 15-fold 
and the specific activity was increased to 9.5 X 10^ units/^g 
(Table 2). 
Reverse Phase HPLC 
Fractions that contained TGF-)3 were pooled, lyophilized 
and resuspended in water with 0.1% trifluoroacetic acid. The 
sample was eluted from the C-8 reverse phase column with an 
acetonitrile gradient (0% to 39%) containing 0.1% TEA (Figure 
2) . TGF-/3 eluted as a single peak at 32% acetonitrile. The 
final degree of purification was 18900 fold. The total 
recovery of 1666% may be attributed to further activation of 
latent TGF-/3 by denaturation in acetonitrile and acidifica­
tion by TFA. 
Analysis of Purified TGF-/Î by SDS-PAGE 
The purified TGF-)3 is homogeneous containing no detect­
able contaminants as determined by SDS-PAGE with or without 
/3-mercaptoethanol stained by a combination of Coomasie blue 
and standard silver staining (Figure 3) . TGF-/3 migrated at 
2 5 KDa, characteristic of its dimeric form and separated into 
two 12.5 KDa monomeric subunits upon reduction. The amino 
acid analysis of the purified protein determined a final 
yield of 162 /lig of TGF-# from 15 grams of starting material 
(Table 2). The amino acid composition, (Figure 4), shows a 
strong match to bovine type-1 TGF-/9 by comparing to the 
reported nucleotide sequence of type-1 bovine TGF-jS (Van 
Obberghen-Schilling et" , 1987). The amino acid sequence 
was determined to 35 residues and matched perfectly with 
type-1 bovine TGF-jS (data not shown) . The specific activity 
of the bovine TGF-/3 is very high at 1.2 X 10® units per ug. 
When compared to commercially prepared type-1 human TGF-p, 
the purified bovine TGF-/3 was 100 fold more active. 
Figure 1. A Biogel P-60 size exclusion column of platelet 
extract 
Two milliliters of sample in 1 M acetic acid was loaded 
on a 1 X 100 cm column and washed with 1 M acetic acid at 
4°C. One hundred fractions of 3.0 ml were collected at 0.25 
ml/min. A: Protein absorbance was detected by spectropho­
tometry at 220 nm (dotted line). One microliter of each 
fraction was tested concurrently in triplicate on CCL64 
(solid line) and R1B-CCL64 (broken line) cells for inhibition 
of ^H-thymidine incorporation. The average ^H-thymidine 
counts of each sample are normalized to the average cpm of a 
control sample to give fold/control. The triplicate values 
were averaged and plotted. TGF-/3 eluted in fractions 57-75 
and failed to inhibit DNA synthesis of R1B-CCL64 cells. 
B: The fold/control of ^H-thymidine incorporation in 
CCL64 cells was normalized to the TGF-)3 receptor mutant RIB-
CCL64 to give a response ratio that identifies specific TGF-/3 
mediated inhibition. 
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Figure 2. Reverse phase HPLC of pooled TGF-jS from the size 
exclusion column 
One milliliter of Biogel P-60 purified TGF-# in water 
containing 0.1% TFA was loaded on a Brownlee RP-300 C-8 
reverse phase column. The sample was eluted with a 
water/acetonitrile gradient according to methods. Fractions 
of various volumes were collected to isolate individual 
peaks. Triplicate samples were assayed as in Figure 1. The 
protein was detected at 220 nm (dotted line). The inhibition 
of ^H-thymidine incorporation due to TGF-(3 is expressed as a 
response ratio (CCL64/R1B; solid line) . TGF-JS eluted in a 
single peak in one milliliter at 32% acetonitrile in fraction 
12. 
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Figure 3. SDS-PAGE of purified bovine platelet T6F-/3 
The purified TGF-/3 was run on a 20% homogeneous SDS-PAGE 
with (B) and without (A) /3-mercaptoethanol as a reducing 
agent. A sample of 0.5 /il of fraction 12 was run. The gel 
was stained with a combination of Coomasie blue-R followed by 
silver staining to enhance sensitivity. TGF-/3 appears as a 
single homogeneous band at 25 KDa without reduction (A) and 
dissociates into the expected two monomers at 12.5 KDa upon 
reduction (B). 
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Figure 4. Amino acid composition of bovine platelet T6F-/3 
The amino acid composition was determined for TGF-p 
isolated from the C-8 reverse phase column (see Materials and 
Methods). The residues per mole is the average of three 
determinations with the standard deviation in parentheses 
unless otherwise stated, see below (*). The tryptophan (Trp) 
and cysteine (Cys) were not determined. The aspartic 
acid/asparagine (Asx) and the glutamic acid/glutamine (Glx) 
were detected as single peaks. The purified TGF-/3 is com­
pared to bovine type-1 TGF-/3 (**) form bovine fibropapilloma 
cells. The (+) designates a close match of the purified 
TGF-p to the type-1 TGF-j3. 
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Residues /mole (mean +/- S.D.) 
Amino acid 
Purified Bovine* Match 
TGF-beta TGF-beta-1 
Ala 5 +/- 1 7 + 
Phe 4 +/- 1 3 ++ 
Gly 18 +/- 1 5 
His 2 +/- 1 3 ++ 
lie 8 +/ — 1 5 
Lys 7 +/- 1 8 ++ 
Leu 10 +/- 8 10 + 
Met 2 +/- 1 1 ++ 
Pro 15 +/- 3 9 
Arg 12 +/- 2 4 
Ser 9 +/ — 1 8 ++ 
Thr 4 +/- 1 3 ++ 
Val 9 +/- 2 7 ++ 
Tyr 4 +/- 1 8 
(Asx) 9 +/- 1 10 ++ 
(Glx) 9 +/- 1 9 + + 
Cys N.D. 9 
Trp N.D. 3 
112 
*: Bovine type-1 TGF-beta determined from the cDNA 
of bovine fibropapilloma cells (Van Obberghen-
Schilling, et al., 1987). 
+: Designates a match. 
++: Designates a close match. 
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DISCUSSION 
A variety of protocols for the purification of TGF-p 
have been published in the past few years. Most procedures 
consist of acid-ethanol extraction of platelets followed by a 
size exclusion column with and without urea (Assoian ^  al., 
198 3), cation exchange chromatography (van den Eijnden-van 
Raaij et al., 1988) and reverse phase HPLC. Size exclusion 
chromatography with then without urea takes advantage of the 
differential migration of TGF-/3 in the column with the two 
treatments. But this scheme demands extensive dialysis of 
fractions prior to assaying and isolation of protein result­
ing in additional losses of TGF-/3 due to adsorption and 
inactivation on the column. Other procedures have avoided 
the use of dénaturants and non-volatile salts but have prob­
lems of specific identification of TGF-/3 in their use of the 
very sensitive bioassay of inhibition of ^H-thymidine by 
CCL64 cells. This bioassay also fails to show specific TGF-(3 
mediated activity. We have overcome these problems by de­
veloping a rapid purification of platelet derived TGF-/3 in 
which a single size exclusion chromatography step is followed 
by reverse phase HPLC. This procedure avoids the use of 
dénaturants and non-volatile salts. Concurrent use of CCL64 
and the TGF-/3 receptor mutant R1B-CCL64 derived from CCL64 
cells in a DNA synthesis assay provides a rapid means for 
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assaying TGF-^. This novel bioassay specifically identifies 
TGF-/3. 
The purification of bovine platelet TGF-/3 results in 
yields approaching 12.5 /xg per liter of blood and 10.8 ij.g per 
gram of platelets. Further increases in yield might be 
achieved by optimizing initial platelet isolation from the 
large volumes of blood. The specific activity of the bovine 
TGF-/3 at 1.2 X 10® units per nq is a 100 fold greater than 
commercially prepared type-1 human TGF-jfl. This may be due to 
the reduction in number of steps and manipulation during the 
purification and also to the elimination of dénaturants such 
as urea, that could inactivate TGF-jS with extended contact. 
It is also noted that the recovery of TGF-/3 increased 
after elution from the C-8 RPLC. Latent platelet derived 
TGF-j0 seems to consist of two pools, one activated by mild 
acidification or proteolysis and another activated by pH 
extremes (Lyons et , 1990; Miyazono et al,., 1988). During 
the preparation described here the first pool of TGF-/3 was 
probably activated by the acid/ethanol extraction and equili­
bration in 1 M acetic acid. The RPLC step which contains 
0.1% trifluoroacetic acid provides an environment at pH 2.0 
that could activate the second pool. The result would be an 
apparent increase in recovery over the course of the purifi­
cation. 
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The bioassay for TGF-p specifically identifies TGF-/3 from 
other potential inhibitors of ^H-thymidine incorporation and 
eliminates the need for western blotting, radioimmunoassays 
or soft agar colony growth assays to monitor the location of 
TGF-jS in the course of purification. It also allows the 
detection of TGF-/Î in the same fractions as a growth stimula­
tor where in other assays TGF-/3 would be obscured. This 
assay has also been successfully employed to identify another 
growth inhibitor we have termed matrixin-A which differs from 
TGF-yS because of its ability to inhibit DNA synthesis in RIB-
CCL64 as well as CCL4 cells. 
The purified bovine TGF-jS seems to be type-1 TGF-#. TGF-
0 is a family of five proteins all immunologically distinct 
but highly homologous. Types 1,2 and 3 all seem to bind the 
same set of three receptors and mediate similar activities 
(Massaguè, 1990) . Bovine type-1 TGF-)3 has been identified in 
bovine fibropapilloma cells (Van Obberghen-Schilling, et al., 
1987). Although our bioassay fails to identify the specific 
type of TGF-/3, the migration of our TGF-j3 on the C-8 RPLC 
and the aminoacid composition indicates this is type-1 TGF-j9. 
The first 35 amino acids of the sequence of the purifed TGF-)3 
matches perfectly with the cDNA derived sequence for bovine 
type-1 TGF-)3. 
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Given the diversity of growth factors and cytokines 
discovered in the past few years and the likely discovery of 
many more, it is important in their identification to be able 
to specifically assign specific cellular activities to a 
growth factor. One way to achieve this in vitro is by using 
mutant cells unresponsive to the growth factor in question, 
concurrently with normal cells in the bioassay. The assay is 
simple, reproducible and precludes the use of antibodies that 
are expensive and sometimes unobtainable. 
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SUMMARY and DISCUSSION 
The extracellular matrix is a complex mixture of pro­
teins that cooperate to maintain cell homeostasis. Many of 
these proteins can affect cell proliferation. During proc­
esses of tissue remodeling, wound healing or disease process­
es where proteases are activated, a cascade of growth regula­
tors including heparan, thrombin and decorin are released 
from the ECM. Binding proteins for growth factors are locat­
ed in the ECM. It seems feasible that the activation of 
proteases in highly regulated cascades in the ECM release 
growth factors such as matrixin-A; TGF-/3, FGF or thrombin. 
These growth factors can then act to both build ECM and guide 
cell growth and differentiation to form functional tissue. 
The first paper in this thesis describes the purifica­
tion and characterization of matrixin-A. The release of 
matrixin-A from the ECM of epithelial cells is mediated by 
plasmin, a highly regulated serum protease. The plasminogen 
activation cascade takes place in the ECM. Plasminogen is 
bound to fibrinogen and fibrin until it is activated by 
active t-PA or u-PA. If the cascade were activated at a 
wound site where plasmin is directly associated with the ECM, 
one of the first events could be the cleavage of fibrin and 
other ECM components to release and or activate growth fac­
tors such as matrixin-A or TGF-j9. 
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Plasmin may not be the only specific activator of these 
factors as matrixin-A release was caused by trypsin. There 
are many other serum and extracellular matrix associated 
serine proteases that could be the primary releasing agent. 
Plasmin can activate latent collagenase which could be the 
matrixin-A releasing agent. 
Potential plasmin mediated release of active ECM related 
growth factors would be a highly regulated process. The 
plasminogen activation cascade is inhibited at many levels by 
protease inhibitors including PAI-1. These inhibitors can be 
induced by the growth factors (Nilsen-Hamilton and Holley, 
1983; Thalacker and Nilsen-Hamilton, 1987; Laiho et al.. 
1986) which points to the possibility of feedback inhibition 
of the cascade that releases the growth factors . 
The second paper describes an improved purification 
scheme for the production of bovine platelet derived TGF-#. 
The scheme takes advantage of the TGF-)3 receptor mutant cell 
line R1B-CCL64 to specifically identify TGF-jS mediated ef­
fects. After the extraction of bovine platelets only two 
purification steps were used to obtain homogenous TGF-j3. 
Important to the research efforts of any laboratory that uses 
growth factors is the availability of highly pure, inexpen­
sive growth factor. The described purification for TGF-jS 
provides this product. 
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